Replies to post #246749 on Biotech Values

[DewDiligence]

GKOS—…seems like they have data to back up one "remove and replace"…

From a medical standpoint, if iDose TR can be replaced once I would think it can be replaced multiple times, thereby offering a bona fide long-term treatment for POAG.

…this is different vs. biodegradable DURYSTA, so the FDA may not be as concerned.

iDose TR implantation does not cause loss of corneal tissue as Durysta does, which is the reason Durysta can’t be repeated on the same eye.

Do you have an estimate for the size of the US and global addressable market for iDose TR, assuming that it is approved for remove and replace? TIA